TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial
Portfolio Pulse from
TransCode Therapeutics has dosed the first patient in the third cohort of its Phase 1 clinical trial for TTX-MC138, following positive safety reviews from earlier cohorts.
January 14, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TransCode Therapeutics has successfully dosed the first patient in the third cohort of its Phase 1 trial for TTX-MC138, with no significant safety issues reported in earlier cohorts.
The dosing of the first patient in Cohort 3 after positive safety reviews from earlier cohorts suggests progress and potential success in the clinical trial, which is likely to positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100